

Superb Diagnostics to Launch Digital Urine Cytology Service with AI-Powered Image Analysis

Superb Dx and AlxMed team up to bring AI-driven urine cytology to Superb Dx's reference lab capabilities, targeting abnormal cells based on TPS 2.0.

HACKENSACK, NJ, UNITED STATES, March 20, 2026 /EINPresswire.com/ -- [Superb Dx](#), a CAP



We recognize the growing need for smaller laboratories and those new to digital urine cytology to efficiently scan, review, and collect quantitative data."

Samuel Chen, CEO of AlxMed

accredited laboratory providing advanced diagnostic services, and [AlxMed](#), an innovator in AI software for urine cytology, today announced a new reference lab service. The collaboration will integrate AlxMed's specialized AI technology into Superb Dx's digital pathology platform, expanding advanced diagnostic tools for the urology market.

AlxMed's solution [AlxURO](#) is designed to assist in the analysis of urine cytology specimens, aiming to improve

accuracy and workflow efficiency in urothelial cell assessment. AlxURO identifies suspicious and atypical cells from a non-invasive urine sample, incorporating The Paris System (TPS 2.0) for Reporting Urinary Cytology. The solution is intended to assist pathologists and laboratory professionals with digital case review and screening workflows.

"Our partnership with AlxMed brings their expertise in urine cytology AI to our growing portfolio of digital solutions," said Gordana Katava, DO, Medical Director of Superb Dx. "It reflects our ongoing commitment towards integrating valuable AI capabilities that meet the specific needs of our diverse customer base."

"We recognize the growing need for smaller laboratories and those new to digital urine cytology to efficiently scan, review, and collect quantitative data," said Samuel Chen, CEO of AlxMed. "Superb Dx brings strong operational capabilities and service quality to the market in a timely and cost-effective manner. We are excited to support them with an integrated and tested solution within their service suite."

Superb Dx will integrate AlxURO™ into its digital pathology ecosystem. The addition of this urine cytology AI further diversifies Superb Dx's offerings for urologists, oncologists and

researchers. To learn more about these solutions or to request a demonstration, visit www.superbdx.com.

About AlxMed

Founded in 2018, AlxMed is transforming cytology with its computational cytology platform. AlxMed extracts clinical insights to enhance patient care. The first application, AlxURO™, finds cells of interest based on The Paris System for Reporting Urinary Cytology (TPS 2.0). AlxURO™ is currently a Research Use Only application. Learn more at AlxMed.com.

About Superb Diagnostics

The Superb Diagnostics team has over 25 years of experience in the commercial and physician-owned laboratory space delivering unparalleled consultative approaches to laboratory services. We provide fast, reliable lab services backed by cutting-edge technology and deep expertise. We offer customized solutions, seamless EMR integration, and nationwide logistics — delivering best-in-class diagnostics that enhance patient care. Learn more at Superbdx.com

Rachel Collins

Superb Diagnostics

+1 551-209-0900

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/900531190>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.